DA29

DA29 (compound 26) potently activates purified human hClpP, with an EC₅₀ of 0.85 μM and an activation rate of 95% at a concentration of 100 μM in cell-free fluorescence assays; it binds to purified human hClpP with a K_d of 185 nM; and it enhances the thermal stability of hClpP in Caco-2 cells^[1].
DA29 exhibits high basolateral permeability in Caco-2 and MDCK-MDR1 cell monolayer models, with BA/AB ratios of 5.91 and 4.61, respectively, suggesting its potential blood-brain barrier penetration ability; meanwhile, it shows weak interaction with P-gp (EC₅₀ = 71 μM)^[1].
DA29 (1-100 μM; 72 h) exhibits cytotoxic activity against the SU-DIPG-36 and SU-DIPG-50 diffuse intrinsic pontine glioma (DIPG) cell lines, with IC₅₀ values of 4.0 μM and 11.6 μM, respectively; it reduces the viability of DIPG tumor organoids DMG2_O and DMG3_O, with IC₅₀ values of 2.57 μM and 1.94 μM, respectively^[1].
DA29 (1 μM; 1-24 h) significantly raises intracellular ROS levels in SU-DIPG-36 cells, with the notable increase detected at 6 h^[1].
DA29 (1.5 μM; 24 h) displaces ClpX from the ClpXP complex, reduces the levels of specific mitochondrial respiratory chain subunits and TFAM, and decreases mtDNA levels in SU-DIPG-36 cells; it also reduces the levels of mitochondrial ribosomal subunits, inhibits polyribosome formation, and disassembles the ClpXP complex^[1].
DA29 (24 h) remodels the lipid profiles of SU-DIPG-36 and SH-SY5Y cells, reduces most lysophosphatidylcholine (LPC) and sphingomyelin (SM) species, and alters the species distribution of triglyceride (TG), which is consistent with the characteristics of impaired mitochondrial function^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.